INS and diabetic retinopathy: TZP was associated with a lower risk of “diabetic retinopathy” vs. GLP-1RA as a class, which persisted vs. lixisenatide, liraglutide, semaglutide and dulaglutide, and following restriction of the analysis to exclude patients on concomitant insulin treatment (Fig. 4A, B; Supplementary Figs. 1, 3, 4, and 5).